

Reply to comments by Laffon et al.: Liver SUV versus stage in Hodgkin's lymphoma: the total amount of uptake may play a role in the inverse relationship

Agostino Chiaravalloti · Orazio Schillaci

Received: 21 September 2014 / Accepted: 23 September 2014 / Published online: 22 October 2014
© Springer-Verlag Berlin Heidelberg 2014

Dear Sir,

We read with great interest the letter from Laffon et al. [1] in which the authors refer to a recently published paper of our group that evaluates the factors affecting 2-deoxy-2-(^{18}F)-fluoro-D-glucose (^{18}F -FDG) uptake in the liver and mediastinum during chemotherapy (CHT) in Hodgkin's lymphoma (HL) [2]. Laffon et al. suggest that the total amount of uptake in malignant tissues of cancer patients may play a role in the reduction of ^{18}F -FDG uptake in the liver at staging in HL (as shown in the report previously cited) [2, 3]. For this reason, the authors suggest that the measurement of the total ^{18}F -FDG that is irreversibly trapped in a pathological tissue (as measured by a formula suggested by Laffon et al. [3]) could help in the explanation of this phenomenon and could be useful when evaluating positron emission tomography/computed tomography (PET/CT) scans of patients with cancer.

We agree with the hypothesis of Laffon and colleagues. We performed a further analysis of the data already published [2], and here we report a graphical representation of the relationship between the maximum standardized uptake value (SUV_{max}) in the mediastinum and the stage of the disease (Fig. 1) that led to results similar to those observed in the liver [2]. In particular, in our study cohort, the SUV_{max} in the mediastinum is significantly related to the extension of HL according to Ann Arbor criteria with a lower SUV_{max} in the mediastinum being related to a higher stage of the disease ($p=0.0385$, Fig. 1) [2]. In agreement with Laffon et al., we can conclude that when a tissue shows an intense tracer uptake, the




Fig. 1 Graphical representation of the linear regression analysis that investigated the relationships between mediastinum SUV_{max} and the stage of HL. Further details can be found in the text and in reference [2]

amount of tracer available to another tissue is reduced (to be specific, the circulating ^{18}F -FDG in the blood as detectable by means of mediastinum SUV_{max}) [4]. We would like to thank Laffon et al. for their detailed comments and suggestions that have greatly improved the results of our study.

References

1. Laffon E, de Clermont H, Lamare F, Marthan R. Liver SUV versus stage in Hodgkin's lymphoma: the total amount of uptake may play a role in the inverse relationship. *Eur J Nucl Med Mol Imaging* 2014. doi:10.1007/s00259-014-2925-1.
2. Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting inpatient liver and mediastinal blood pool (^{18}F -FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging* 2014;41:1123–32. doi:10.1007/s00259-014-2703-0.
3. Laffon E, de Clermont H, Lamare F, Marthan R. Estimating the amount of FDG uptake in physiological tissues. *Nucl Med Biol* 2014;41:717–20.
4. Boellaard R. Standards for PET image acquisition and quantitative data analysis. *J Nucl Med* 2009;50:11S–20S.

A. Chiaravalloti (✉) · O. Schillaci
Department of Biomedicine and Prevention, University Tor Vergata,
Viale Oxford 81, 00133 Rome, Italy
e-mail: agostino.chiaravalloti@gmail.com

O. Schillaci
IRCCS Neuromed, Pozzilli, Italy